Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

Mayo Clinic Specialty Pharmacy

Actemra

Afinitor

Alecensa

Alunbrig

Ayvakit

Benlysta

Bosulif

Braftovi

Cabometyx

Copiktra

Cosentyx

Cotellic

Daurismo

Enbrel

Erleada

Erivedge

Esbriet

Farydak

Gavreto

Gilotrif

Ibrance

Idhifa

Imbruvica

Inlyta

Inqovi

Inrebic

Iressa

Jakafi

Koselugo

Lonsurf

Lorbrena

Lumakras

Lynparza

Mekinist

Mektovi

Nerlynx

Nexavar

Nubeqa

Odomzo

Ofev

Olumiant

Onureg

Piqray

Promacta

Retevmo

Rozlytrek

Rubraca

Stelara

Stivarga

Sutent

Tabrecta

Tafinlar

Tagrisso

Talzenna

Tarceva

Tasigna

Truseltiq

Tykerb

Venclexta

Vizimpro

Vitravki

Votrient

Vyndamax

Vyndaqel

Xalkori

Xpovio

Xtandi

Yonsa

Zejula

Zydelig

Zykadia

Rinvoq | Mayo Clinic Specialty Pharmacy

Which health plans does Mayo Clinic Specialty Pharmacy have contracts with?

Does Mayo Clinic Specialty Pharmacy work closely with Rinvoq and AbbVie Inc.?

Does Mayo Clinic Specialty Pharmacy offer services for Rinvoq patients?

What conditions does Mayo Clinic Specialty Pharmacy support?

How does Mayo Clinic Specialty Pharmacy help with insurance?